XML 51 R31.htm IDEA: XBRL DOCUMENT v3.3.1.900
BUSINESS SEGMENT INFORMATION (Tables)
 12 Months Ended
Dec. 31, 2015
Segment Reporting [Abstract]  
Schedules of Concentration of Risk, by Risk Factor [Table Text Block]
Products are sold principally to wholesalers, and to a lesser extent, directly to distributors, retailers, hospitals, clinics, government agencies and pharmacies. Gross revenues to the three largest pharmaceutical wholesalers in the U.S. as a percentage of global gross revenues were as follows:
 
 
2015
 
2014
 
2013
McKesson Corporation
 
21
%
 
20
%
 
19
%
AmerisourceBergen Corporation
 
16
%
 
17
%
 
15
%
Cardinal Health, Inc.
 
12
%
 
12
%
 
14
%
Schedule of Revenue from External Customers and Long-Lived Assets, by Geographical Areas [Table Text Block]
Selected geographic area information was as follows:
 
 
Revenues
 
Property, Plant and Equipment
Dollars in Millions
 
2015
 
2014
 
2013
 
2015
 
2014
United States
 
$
8,188

 
$
7,716

 
$
8,318

 
$
3,681

 
$
3,686

Europe
 
3,491

 
3,592

 
3,930

 
616

 
597

Rest of the World
 
4,142

 
3,459

 
3,295

 
115

 
134

Other(a) 
 
739

 
1,112

 
842

 
—

 
—

Total
 
$
16,560

 
$
15,879

 
$
16,385

 
$
4,412

 
$
4,417


(a)
Other revenues include royalties and alliance-related revenues for products not sold by our regional commercial organizations.
Schedule of Revenue from External Customers by Products and Services [Table Text Block]
The composition of total revenues was as follows:
 
 
Year Ended December 31,
Dollars in Millions
 
2015
 
2014
 
2013
Net product sales
 
$
14,045

 
$
11,660

 
$
12,304

Alliance revenues
 
2,408

 
3,828

 
3,804

Other revenues
 
107

 
391

 
277

Total Revenues
 
$
16,560

 
$
15,879

 
$
16,385

Product revenues were as follows:
 
 
Year Ended December 31,
Dollars in Millions
 
2015
 
2014
 
2013
Virology
 
 
 
 
 
 
Baraclude (entecavir)
 
$
1,312

 
$
1,441

 
$
1,527

Hepatitis C Franchise
 
1,603

 
256

 
—

Reyataz (atazanavir sulfate) Franchise
 
1,139

 
1,362

 
1,551

Sustiva (efavirenz) Franchise
 
1,252

 
1,444

 
1,614

Oncology
 
 
 
 
 
 
Empliciti (elotuzumab)
 
3

 
—

 
—

Erbitux* (cetuximab)
 
501

 
723

 
696

Opdivo (nivolumab)
 
942

 
6

 
—

Sprycel (dasatinib)
 
1,620

 
1,493

 
1,280

Yervoy (ipilimumab)
 
1,126

 
1,308

 
960

Neuroscience
 
 
 
 
 
 
Abilify* (aripiprazole)
 
746

 
2,020

 
2,289

Immunoscience
 
 
 
 
 
 
Orencia (abatacept)
 
1,885

 
1,652

 
1,444

Cardiovascular
 
 
 
 
 
 
Eliquis (apixaban)
 
1,860

 
774

 
146

Mature Products and All Other
 
2,571

 
3,400

 
4,878

Total Revenues
 
$
16,560

 
$
15,879

 
$
16,385